Recently published in the New England Journal of Medicine, findings from the pivotal phase 3 trial, KEYNOTE-564, underscore a crucial development in adjuvant therapy for patients diagnosed with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence. Led by Dr. Toni Choueiri, the study demonstrates the remarkable efficacy of pembrolizumab, an immunotherapy drug, in extending overall survival rates following surgical intervention. Patients administered pembrolizumab exhibited a notable 38% reduction in the risk of mortality compared to those receiving a placebo. This pivotal trial r ..read more

NEW REPORT FINDS KIDNEY CANCER PATIENTS ARE BEING MISDIAGNOSED, CONFUSED & UN-INFORMED Annual survey report from Kidney Cancer UK spotlights problematic communication gaps during kidney cancer diagnoses, and urges health professionals to be more proactive with signposting to read/ download report free support services from the charity sector One in four kidney cancer patients are being initially misdiagnosed – delaying their access to treatment More than a third are “unhappy” with how they were told they had kidney cancer, and over half wanted more information Only 1% of patients were g ..read more

Kidney Cancer UK is delighted to present our first Webinar for 2024 on Tuesday January 16th at 6pm, ‘Counselling – Who Needs It?’ REGISTER HERE This Webinar will explore the benefits of counselling and how it can help and support patient’s, their families, and carers in dealing with a diagnosis of kidney cancer. Presented by Kidney Cancer UK’s qualified counsellor, Carolyn Bartlett (MBACP), feature a patient sharing their experience, followed by a full Q&A session. This promises to be an insightful webinar. To attend you will be required to register for free. Please follow the button below ..read more

Kidney Cancer UK is delighted to present our first Webinar for 2024 on Tuesday January 16th at 6pm, ‘Counselling – Who Needs It?’ REGISTER HERE This Webinar will explore the benefits of counselling and how it can help and support patient’s, their families, and carers in dealing with a diagnosis of kidney cancer. Presented by Kidney Cancer UK’s qualified counsellor, Carolyn Bartlett (MBACP), feature a patient sharing their experience, followed by a full Q&A session. This promises to be an insightful webinar. To attend you will be required to register for free. Please follow the button below ..read more

Merck partners with HiberCell for Phase Ib renal carcinoma trial The Phase Ib trial will evaluate the combination therapy of Welireg and HC-7366 in patients with clear cell renal cell carcinoma and is expected to start in Q1 2024 Merck & Co (MSD) and HiberCell have partnered to conduct a Phase Ib trial to evaluate the combination therapy of MSD’s Welireg (belzutifan) and HiberCell’s HC-7366 for treating clear cell renal cell carcinoma (RCC). Welireg is an oral hypoxia-inducible factor-2α (HIF-2α) inhibitor. It was approved as a treatment for certain patients with von Hippel-Lindau (VHL) di ..read more

Living with a rare disease can be challenging enough, especially when it impacts you physically. But for those living with VHL disease, a rare form of kidney cancer, their determination, resilience, and strength is tested daily. In a recent study involving 123 family members from 48 VHL families, 50% of those with VHL mutations and 36% of those without experienced high levels of distress. The discourse surrounding rare diseases such as VHL has a lesser focus on the mental implications that come with diagnosis, as well as proceeding with life afterwards and genetic testing. What is VHL? Von-Hip ..read more

The post Santa In the City Festive Run appeared first on Kidney Cancer UK ..read more

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery. The results will be presented at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Oct. 23, 2023 (poster 1887P) by Primo N. Lara, Jr., MD, lead author on the abstract. Lara is distinguished professor of medi ..read more

The drug response predictor companion diagnostic for dovinitib (DRP-Dovitinib) demonstrates potential to identify patients with advanced renal cell carcinoma (RCC) who are most likely to respond positively from its treatment, according to a study in PLOS. In the sensitive group, median progression-free survival (PFS) was 3.8 months, and in the sorafenib arm, median PFS was 3.6 months (hazard ratio [HR], 0.71; 95% CI, 0.51-1.01). The median overall survival (OS) in the sensitive group was 15.0 months. In the sorafenib arm, median OS was 11.2 months (HR, 0.69; 95% CI, 0.48-0.99). Observed clinic ..read more

Exploring how to match treatments to patients Patients with advanced or metastatic kidney cancer now have a range of options in terms of drug treatment. However, at the moment, we don’t know which drugs might work better for which patient. Pear-Bio is a UK-based biotech company that has developed a system that takes a fresh biopsy from the tumour, splits it into equal parts, and places each part in a separate 3D culture. They then grow these, leaving one without treatment, and treating the others with different drugs that might be used. Their hope is that their system can be used to predict wh ..read more